Literature DB >> 22884969

Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients.

Chun Yang, Zhi-qiang Zhou, Zhi-qin Gao, Jin-yun Shi, Jian-Jun Yang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22884969     DOI： 10.1016/j.biopsych.2012.07.022

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  22 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 2.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

Review 3.  Esketamine: a glimmer of hope in treatment-resistant depression.

Authors:  Upinder Kaur; Bhairav Kumar Pathak; Amit Singh; Sankha Shubhra Chakrabarti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-11-19       Impact factor: 5.270

4.  Everolimus induced mood changes in breast cancer patients: a case-control study.

Authors:  Olivier Mir; Alexandre Salvador; Sarah Dauchy; Stanislas Ropert; Cédric Lemogne; Raphaël Gaillard
Journal:  Invest New Drugs       Date:  2017-12-18       Impact factor: 3.850

5.  GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.

Authors:  Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Bipolar Disord       Date:  2016-11-29       Impact factor: 6.744

6.  Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3.

Authors:  Steven F Grieco; Dmitry Velmeshev; Marco Magistri; Hagit Eldar-Finkelman; Mohammad A Faghihi; Richard S Jope; Eleonore Beurel
Journal:  World J Biol Psychiatry       Date:  2016-10-10       Impact factor: 4.132

7.  Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.

Authors:  C N Haile; J W Murrough; D V Iosifescu; L C Chang; R K Al Jurdi; A Foulkes; S Iqbal; J J Mahoney; R De La Garza; D S Charney; T F Newton; S J Mathew
Journal:  Int J Neuropsychopharmacol       Date:  2013-10-08       Impact factor: 5.176

8.  Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition.

Authors:  Steven F Grieco; Yuyan Cheng; Hagit Eldar-Finkelman; Richard S Jope; Eléonore Beurel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-08-16       Impact factor: 5.067

9.  Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.

Authors:  Eléonore Beurel; Steven F Grieco; Celeste Amadei; Kimberlee Downey; Richard S Jope
Journal:  Bipolar Disord       Date:  2016-09-30       Impact factor: 6.744

Review 10.  Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Front Pharmacol       Date:  2013-12-27       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.